{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T10:07:50Z","timestamp":1775124470289,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,7]],"date-time":"2017-01-07T00:00:00Z","timestamp":1483747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Brasileira de Reumatologia (English Edition)"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.rbre.2017.01.001","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T21:15:45Z","timestamp":1487193345000},"page":"254-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of postmenopausal osteoporosis: a literature-based algorithm for use in the public health care system"],"prefix":"10.1016","volume":"57","author":[{"given":"Ellen Luz Pereira","family":"Caires","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mailze Campos","family":"Bezerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Fl\u00e1via Torquato de Ara\u00fajo","family":"Junqueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila M\u00e1rcia de Ara\u00fajo","family":"Fontenele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana Cristina de Albuquerque","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina Brasil","family":"d\u2019Alva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rbre.2017.01.001_bib0310","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.rbre.2017.01.001_bib0315","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1503\/cmaj.100771","article-title":"2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary","volume":"182","author":"Papaioannou","year":"2010","journal-title":"CMAJ"},{"key":"10.1016\/j.rbre.2017.01.001_bib0320","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10522-011-9344-5","article-title":"Physiology of the aging bone and mechanisms of action of bisphosphonates","volume":"12","author":"Dominguez","year":"2011","journal-title":"Biogerontology"},{"key":"10.1016\/j.rbre.2017.01.001_bib0325","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonates in osteoporosis","volume":"95","author":"Watts","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.rbre.2017.01.001_bib0330","series-title":"World Health Organization Assessment of fracture risk and application to screening for postmenopausal osteoporosis. Geneva, Switzerland","author":"Organization WH","year":"1994"},{"key":"10.1016\/j.rbre.2017.01.001_bib0335","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rbre.2017.01.001_bib0340","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.rbre.2017.01.001_bib0345","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.rbre.2017.01.001_bib0350","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.rbre.2017.01.001_bib0355","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rbre.2017.01.001_bib0360","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.rbre.2017.01.001_bib0365","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1185\/030079908X253717","article-title":"Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies","volume":"24","author":"Harris","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rbre.2017.01.001_bib0370","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00198-008-0653-8","article-title":"Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data","volume":"20","author":"Cranney","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.rbre.2017.01.001_bib0375","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rbre.2017.01.001_bib0380","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.189","article-title":"Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001\u20132008","volume":"26","author":"Siris","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.rbre.2017.01.001_bib0385","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1302\/0301-620X.89B3.18146","article-title":"Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution","volume":"89","author":"Goh","year":"2007","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.rbre.2017.01.001_bib0390","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/ageing\/afp106","article-title":"Spontaneous femoral shaft fracture after long-term alendronate","volume":"38","author":"Ali","year":"2009","journal-title":"Age Ageing"},{"key":"10.1016\/j.rbre.2017.01.001_bib0395","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.rbre.2017.01.001_bib0400","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3899\/jrheum.100221","article-title":"Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons","volume":"38","author":"Khan","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rbre.2017.01.001_bib0405","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rbre.2017.01.001_bib0410","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.rbre.2017.01.001_bib0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.rbre.2017.01.001_bib0420","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","article-title":"Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate","volume":"358","author":"Lenart","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rbre.2017.01.001_bib0425","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rbre.2017.01.001_bib0430","first-page":"61","article-title":"A retrospective analysis of all atypical femur fractures seen in a large California HMO from the years 2007 to 2009","volume":"25","author":"Dell","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.rbre.2017.01.001_bib0435","series-title":"Alerta terap\u00eautico em farmacovigil\u00e2ncia. Uso de bisfosfonatos associado ao risco de osteonecrose de mand\u00edbula. S\u00e3o Paulo","author":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria","year":"2013"},{"key":"10.1016\/j.rbre.2017.01.001_bib0440","series-title":"FDA Drug Safety Communication: safety update for osteoporosis drugs, bisphosphonates, and atypical fractures","author":"US Food and Drug Administration","year":"2010"},{"key":"10.1016\/j.rbre.2017.01.001_bib0445","series-title":"European Medicines Agency concludes class review of bisphosphonates and atypical fractures. Rare atypical fractures of the femur: a class effect of bisphosphonates. London","author":"European Medicines Agency","year":"2011"},{"key":"10.1016\/j.rbre.2017.01.001_bib0450","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jbmr.233","article-title":"Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996\u20132007","volume":"26","author":"Wang","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.rbre.2017.01.001_bib0455","first-page":"324","article-title":"Bisphosphonates for treatment of osteoporosis expected benefits, potential harms, and drug holidays","volume":"60","author":"Brown","year":"2014","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.rbre.2017.01.001_bib0460","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMc062792","article-title":"Prolonged bisphosphonate release after treatment in children","volume":"356","author":"Papapoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rbre.2017.01.001_bib0465","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.rbre.2017.01.001_bib0470","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial","volume":"25","author":"Schwartz","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.rbre.2017.01.001_bib0475","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.rbre.2017.01.001_bib0480","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.rbre.2017.01.001_bib0485","first-page":"3109","article-title":"Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women 1","volume":"85","author":"Tonino","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.rbre.2017.01.001_bib0490","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","article-title":"Intravenous zoledronic acid 5mg in the treatment of postmenopausal women with low bone density previously treated with alendronate","volume":"41","author":"McClung","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.rbre.2017.01.001_bib0495","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rbre.2017.01.001_bib0500","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1007\/s00198-015-3234-7","article-title":"Denosumab treatment in postmenopausal women with osteoporosis for up to 9 years: results through year 6 of the freedom extension","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.rbre.2017.01.001_bib0505","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.rbre.2017.01.001_bib0510","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.rbre.2017.01.001_bib0515","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.292.4.490","article-title":"Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases","volume":"292","author":"Hofbauer","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.rbre.2017.01.001_bib0520","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/jbmr.2480","article-title":"Sustained modeling-based bone formation during adulthood in Cynomolgus monkeys may contribute to continuous BMD gains with denosumab","volume":"30","author":"Ominsky","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.rbre.2017.01.001_bib0525","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF03194365","article-title":"Parathyroid hormone in the treatment of involutional osteoporosis: back to the future","volume":"7","author":"Reginster","year":"1997","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.rbre.2017.01.001_bib0530","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rbre.2017.01.001_bib0535","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1016\/j.rbre.2017.01.001_bib0540","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.rbre.2017.01.001_bib0545","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI6610","article-title":"Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone","volume":"104","author":"Jilka","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.rbre.2017.01.001_bib0550","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1530\/EJE-11-0740","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study","volume":"166","author":"Jakob","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.rbre.2017.01.001_bib0555","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00198-009-1168-7","article-title":"Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis","volume":"21","author":"Stepan","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.rbre.2017.01.001_bib0560","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1359\/jbmr.070603","article-title":"Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study","volume":"22","author":"Graeff","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.rbre.2017.01.001_bib0565","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1359\/jbmr.090416","article-title":"Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study","volume":"24","author":"Graeff","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.rbre.2017.01.001_bib0570","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00198-008-0661-8","article-title":"Assessing response to osteoporosis therapy","volume":"19","author":"Lewiecki","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.rbre.2017.01.001_bib0575","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","article-title":"Treatment failure in osteoporosis","volume":"23","author":"Diez-Perez","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.rbre.2017.01.001_bib0580","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"McClung","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.rbre.2017.01.001_bib0585","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","article-title":"Risk of new vertebral fracture in the year following a fracture","volume":"285","author":"Lindsay","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.rbre.2017.01.001_bib0590","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.rbre.2017.01.001_bib0595","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12020-016-0900-2","article-title":"The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis","volume":"52","author":"Vasikaran","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.rbre.2017.01.001_bib0600","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1185\/03007995.2015.1016605","article-title":"Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy","volume":"31","author":"Modi","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rbre.2017.01.001_bib0605","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.rbre.2017.01.001_bib0610","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/jbmr.1496","article-title":"Risk factors for prediction of inadequate response to antiresorptives","volume":"27","author":"D\u00edez-P\u00e9rez","year":"2012","journal-title":"J Bone Miner Res"}],"container-title":["Revista Brasileira de Reumatologia (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2255502117300019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2255502117300019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T04:51:56Z","timestamp":1536036716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2255502117300019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S2255502117300019"],"URL":"https:\/\/doi.org\/10.1016\/j.rbre.2017.01.001","relation":{},"ISSN":["2255-5021"],"issn-type":[{"value":"2255-5021","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of postmenopausal osteoporosis: a literature-based algorithm for use in the public health care system","name":"articletitle","label":"Article Title"},{"value":"Revista Brasileira de Reumatologia (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rbre.2017.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rbr.2016.12.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}